I'm LongbridgeAI, I can summarize articles.Jim Cramer recommended buying CAVA Group, citing its appealing concept, and suggested ImmunityBio as a speculative position. He also likes Trulieve Cannabis and advised holding Ashland. UBS analysts upgraded CAVA and maintained a Buy rating on Ashland with raised price targets. Despite these recommendations, shares for CAVA, ImmunityBio, Trulieve, and Ashland all declined on Tuesday.
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying CAVA Group, Inc. (NYSE:CAVA). “I think it's the best of the new concepts. I think there's something there for everybody. There really is. It's tasty, clean, fun,” he added.
Supporting his view, UBS analyst Dennis Geiger, on June 10, upgraded Cava Group from Neutral to Buy and raised the price target from $85 to $90.
When asked about ImmunityBio, Inc. (NASDAQ:IBRX), he said, “I will tell you, that's going to be your spec. Remember, in ‘How to Make Money in Any Market,’ I encourage speculation, as long as it's only one position. If you go to two positions, then I don't encourage it. Let Immunitybio be your speculation.”
As per the recent news, ImmunityBio, on June 1, presented data at the American Society of Clinical Oncology Annual Meeting about its Phase 3 studies in advanced non-small cell lung cancer.
Cramer said he likes Trulieve Cannabis Corp. (NYSE:TRLV), adding that it's a “terrific spec.”
Trulieve Cannabis became the first American marijuana company to list on a major U.S. stock exchange. Trulieve shares began trading on the NYSE under the symbol TRLV on June 10.
The Mad Money host recommended holding on to Ashland Inc. (NYSE ASH), adding that it could go higher.
Lending support to his choice, UBS analyst Joshua Spector, on June 10, maintained Ashland with a Buy rating and raised the price target from $66 to $72
Price Action:
- CAVA shares fell 2.5% to settle at $87.30 on Tuesday.
- Immunitybio shares fell 5.8% to close at $6.72.
- Trulieve Cannabis shares dipped 4.7% to close at $9.40 on Tuesday.
- Ashland shares declined 1.3% to settle at $64.56.
Photo via Shutterstock